• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴西卫生专业人员针对 SARS-CoV-2 的体液免疫的纵向研究:加强针和再感染对抗体动态的影响。

Longitudinal study of humoral immunity against SARS-CoV-2 of health professionals in Brazil: the impact of booster dose and reinfection on antibody dynamics.

机构信息

Grupo de Pesquisa em Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.

Grupo de Imunologia de Doenças Virais, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.

出版信息

Front Immunol. 2023 Jul 14;14:1220600. doi: 10.3389/fimmu.2023.1220600. eCollection 2023.

DOI:10.3389/fimmu.2023.1220600
PMID:37520570
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10376701/
Abstract

INTRODUCTION

The pandemic caused by SARS-CoV-2 has had a major impact on health systems. Vaccines have been shown to be effective in improving the clinical outcome of COVID-19, but they are not able to fully prevent infection and reinfection, especially that caused by new variants.

METHODS

Here, we tracked for 450 days the humoral immune response and reinfection in 52 healthcare workers from Brazil. Infection and reinfection were confirmed by RT-qPCR, while IgM and IgG antibody levels were monitored by rapid test.

RESULTS

Of the 52 participants, 19 (36%) got reinfected during the follow-up period, all presenting mild symptoms. For all participants, IgM levels dropped sharply, with over 47% of them becoming seronegative by the 60th day. For IgG, 90% of the participants became seropositive within the first 30 days of follow-up. IgG antibodies also dropped after this period reaching the lowest level on day 270 (68.5 ± 72.3, p<0.0001). Booster dose and reinfection increased the levels of both antibodies, with the interaction between them resulting in an increase in IgG levels of 130.3 arbitrary units.

CONCLUSIONS

Overall, our data indicate that acquired humoral immunity declines over time and suggests that IgM and IgG antibody levels are not associated with the prevention of reinfection.

摘要

简介

由 SARS-CoV-2 引起的大流行对卫生系统产生了重大影响。疫苗已被证明能有效改善 COVID-19 的临床结果,但它们不能完全预防感染和再次感染,尤其是新变体引起的感染和再次感染。

方法

在这里,我们跟踪了来自巴西的 52 名医护人员 450 天的体液免疫反应和再次感染情况。通过 RT-qPCR 确认感染和再次感染,通过快速检测监测 IgM 和 IgG 抗体水平。

结果

在随访期间,52 名参与者中有 19 名(36%)再次感染,所有再次感染的参与者均表现出轻微症状。对于所有参与者,IgM 水平急剧下降,超过 47%的人在第 60 天呈血清阴性。对于 IgG,90%的参与者在随访的前 30 天内呈血清阳性。在此期间之后,IgG 抗体也下降,在第 270 天达到最低水平(68.5 ± 72.3,p<0.0001)。加强剂量和再次感染增加了两种抗体的水平,它们之间的相互作用导致 IgG 水平增加了 130.3 个单位。

结论

总体而言,我们的数据表明,获得的体液免疫随时间推移而下降,并表明 IgM 和 IgG 抗体水平与预防再次感染无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/995dbb55b27b/fimmu-14-1220600-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/df46050d2821/fimmu-14-1220600-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/328b6b734df0/fimmu-14-1220600-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/d9c113bf5c9e/fimmu-14-1220600-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/1e11ddfe1366/fimmu-14-1220600-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/def3992cb8f6/fimmu-14-1220600-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/f6877493a2d8/fimmu-14-1220600-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/995dbb55b27b/fimmu-14-1220600-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/df46050d2821/fimmu-14-1220600-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/328b6b734df0/fimmu-14-1220600-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/d9c113bf5c9e/fimmu-14-1220600-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/1e11ddfe1366/fimmu-14-1220600-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/def3992cb8f6/fimmu-14-1220600-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/f6877493a2d8/fimmu-14-1220600-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eb0/10376701/995dbb55b27b/fimmu-14-1220600-g007.jpg

相似文献

1
Longitudinal study of humoral immunity against SARS-CoV-2 of health professionals in Brazil: the impact of booster dose and reinfection on antibody dynamics.巴西卫生专业人员针对 SARS-CoV-2 的体液免疫的纵向研究:加强针和再感染对抗体动态的影响。
Front Immunol. 2023 Jul 14;14:1220600. doi: 10.3389/fimmu.2023.1220600. eCollection 2023.
2
Antibody response and risk of reinfection over 2 years among the patients with first wave of COVID-19.新冠病毒感染第 1 波患者 2 年内的抗体反应和再感染风险。
Clin Microbiol Infect. 2024 Apr;30(4):522-530. doi: 10.1016/j.cmi.2023.12.017. Epub 2023 Dec 22.
3
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.在无症状至轻症 COVID-19 感染至少 8 个月后,仍能产生强大的体液和细胞免疫反应,并降低再次感染的风险。
J Intern Med. 2022 Jan;291(1):72-80. doi: 10.1111/joim.13387. Epub 2021 Sep 27.
4
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.新型冠状病毒感染后长达13个月的抗体反应演变及再次感染风险。
EBioMedicine. 2021 Sep;71:103561. doi: 10.1016/j.ebiom.2021.103561. Epub 2021 Aug 27.
5
Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain: the ProHEpiC-19 study.COVID-19 大流行期间西班牙大型医护人员队列中体液免疫反应的 17 个月动态:ProHEpiC-19 研究。
BMC Infect Dis. 2022 Sep 3;22(1):721. doi: 10.1186/s12879-022-07696-6.
6
Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil.巴西再次感染 SARS-CoV-2 患者的遗传证据和宿主免疫反应
Emerg Infect Dis. 2021 May;27(5):1446-1453. doi: 10.3201/eid2705.204912. Epub 2021 Apr 12.
7
Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19.从 COVID-19 第一波疫情中康复后,再次感染的风险较低,且与血清学反应有关。
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2597-2604. doi: 10.1007/s10096-021-04335-x. Epub 2021 Aug 11.
8
Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.在接受利妥昔单抗治疗的自身免疫性疾病患者中,第二次和第三次接种 SARS-CoV-2 疫苗后的细胞和体液反应:特异性 T 细胞免疫持续时间更长,并对 SARS-CoV-2 再感染起到保护作用。
Front Immunol. 2023 Apr 27;14:1146841. doi: 10.3389/fimmu.2023.1146841. eCollection 2023.
9
Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.阿根廷卫生保健工作者对 SARS-CoV-2 免疫力的纵向随访:接种卫星 V 疫苗后体液反应和中和能力的持久性。
mSphere. 2023 Jun 22;8(3):e0066222. doi: 10.1128/msphere.00662-22. Epub 2023 Apr 18.
10
[Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].[对感染新冠病毒疾病并接种新冠疫苗的医护人员的新冠病毒特异性体液免疫和细胞免疫值的调查]
Mikrobiyol Bul. 2022 Jul;56(3):480-492. doi: 10.5578/mb.20229708.

引用本文的文献

1
SARS-CoV-2-specific humoral and cellular immunity assessment in Peruvian vaccinated population: a cross-sectional study.秘鲁接种疫苗人群中新冠病毒特异性体液免疫和细胞免疫评估:一项横断面研究
PeerJ. 2025 Jul 15;13:e19651. doi: 10.7717/peerj.19651. eCollection 2025.
2
Circulating Antibodies Against Common Cold Coronaviruses Do Not Interfere with Immune Responses to Primary or Booster SARS-CoV-2 mRNA Vaccines.针对普通感冒冠状病毒的循环抗体不会干扰对SARS-CoV-2 mRNA 疫苗初次或加强免疫的免疫反应。
Vaccines (Basel). 2025 May 21;13(5):547. doi: 10.3390/vaccines13050547.
3
Dynamic Changes and Trends of SARS-CoV-2 Antibodies Induced by Infection and Vaccination Across Multiple Time Points.

本文引用的文献

1
Antibody Response to Omicron BA.4-BA.5 Bivalent Booster.对奥密克戎BA.4-BA.5二价加强针的抗体反应
N Engl J Med. 2023 Feb 9;388(6):567-569. doi: 10.1056/NEJMc2213907. Epub 2023 Jan 11.
2
IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study.接种 BNT162b2 和 mRNA-1273 疫苗后 8 个月内医护人员 IgG 抗 RBD 水平:一项单中心研究。
Front Cell Infect Microbiol. 2022 Nov 30;12:1035155. doi: 10.3389/fcimb.2022.1035155. eCollection 2022.
3
Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection.
感染和接种疫苗后多个时间点诱导产生的SARS-CoV-2抗体的动态变化及趋势
J Med Virol. 2025 Jan;97(1):e70161. doi: 10.1002/jmv.70161.
4
Genetic, Clinical, Epidemiological, and Immunological Profiling of IgG Response Duration after SARS-CoV-2 Infection.新型冠状病毒感染后 IgG 反应持续时间的遗传、临床、流行病学和免疫学特征分析。
Int J Mol Sci. 2024 Aug 10;25(16):8740. doi: 10.3390/ijms25168740.
5
COVID-19 Antibody Levels among Various Vaccination Groups, One-Year Antibody Follow-Up in Two University Hospitals from Western and Central Turkey.土耳其西部和中部两家大学医院不同疫苗接种组的COVID-19抗体水平,为期一年的抗体随访
Vaccines (Basel). 2024 Jan 7;12(1):59. doi: 10.3390/vaccines12010059.
新型冠状病毒感染后的纵向抗体滴度、亲和力及中和反应。
Heliyon. 2022 Nov 19;8(11):e11676. doi: 10.1016/j.heliyon.2022.e11676. eCollection 2022 Nov.
4
SARS-CoV-2 antibodies persist up to 12 months after natural infection in healthy employees working in non-medical contact-intensive professions.SARS-CoV-2 抗体在非医疗接触密集型职业的健康员工自然感染后可持续长达 12 个月。
Int J Infect Dis. 2023 Jan;126:155-163. doi: 10.1016/j.ijid.2022.11.025. Epub 2022 Nov 24.
5
A Shift in SARS-CoV-2 Omicron Variant's Entry Pathway Might Explain Different Clinical Outcomes.SARS-CoV-2 奥密克戎变异株进入途径的转变可能解释了不同的临床结局。
MEDICC Rev. 2022 Oct 31;24(3-4):68-71. doi: 10.37757/mr2022.v24.n3-4.10.
6
Acute and postacute sequelae associated with SARS-CoV-2 reinfection.与 SARS-CoV-2 再感染相关的急性和后期后遗症。
Nat Med. 2022 Nov;28(11):2398-2405. doi: 10.1038/s41591-022-02051-3. Epub 2022 Nov 10.
7
Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.瑞士一项多中心队列研究:根据德尔塔和奥密克戎变异株流行期间的基线免疫状态和加强针接种情况,评估卫生专业人员感染 COVID-19 的风险和症状。
PLoS Med. 2022 Nov 7;19(11):e1004125. doi: 10.1371/journal.pmed.1004125. eCollection 2022 Nov.
8
Patterns of reported infection and reinfection of SARS-CoV-2 in England.英格兰报告的 SARS-CoV-2 感染和再感染模式。
J Theor Biol. 2023 Jan 7;556:111299. doi: 10.1016/j.jtbi.2022.111299. Epub 2022 Oct 15.
9
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.医护人员中,mRNA 疫苗接种与未接种者,初次感染奥密克戎(B.1.1.529)BA.1 或 前奥密克戎 SARS-CoV-2 对 BA.2 再感染的保护作用:一项病例对照研究。
Lancet Infect Dis. 2023 Jan;23(1):45-55. doi: 10.1016/S1473-3099(22)00578-3. Epub 2022 Sep 21.
10
COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022.2021 年 1 月至 2022 年 4 月,13 个美国州 18 岁及以上接种和未接种疫苗的成年人因 COVID-19 住院的情况。
JAMA Intern Med. 2022 Oct 1;182(10):1071-1081. doi: 10.1001/jamainternmed.2022.4299.